Blizard Institute - Barts and The London

Doris Lanz


Research Trial Coordinator

Telephone: 020 7882 5636


Research Coordinator, working on PIMS and FINS trials. She has previously coordinated trials in women’s health, mental health and cancer research, in the UK and Switzerland. She also has experience in delivering patient and public involvement activities, clinical trials quality assurance and designing and delivering GCP training. Special interests include methods to improve trial efficiency and trial manager skills recognition and development.


Research Interests:

GEM (Guided E-Learning for Managers)

SALVO (Cell Salvage in Obstetrics)

PIMS (Positioning In Macular Hole Surgery)

FINS (Faecal Incontinence Intervention Study)


Russell J, Berney L, Stansfeld S, Lanz D, Kerry S, Chandola T, Bhui K. The role of qualitative research in adding value to a randomised controlled trial: lessons from a pilot study of a guided e-learning intervention for managers to improve employee wellbeing and reduce sickness absence. Trials; 2016 Aug 9;17(1):396. PubMed PMID: 27507134.

Stansfeld SA, Berney L, Bhui K, Chandola T, Costelloe C, Hounsome N, Kerry S, Lanz D, Russell J. Pilot study of a randomised trial of a guided e-learning health promotion intervention for managers based on management standards for the improvement of employee well-being and reduction of sickness absence: the GEM (Guided E-learning for Managers) study. Southampton (UK): NIHR Journals Library; 2015 Aug. PubMed PMID: PMID: 26269873

Von Moos R, Roth A, Ruhstaller T, Widmer L, Uhlmann C, Cathomas R, Köberle D, Simcock M, Lanz D, Popescu R. Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03). Onkologie. 2010;33(6):295-9.  PubMed PMID: 20523092.

Schuller JC, Mayer M, Lanz D, Schmitz SF, Brauchli P, Leupin N. A novel diagram and complement to the CONSORT chart for presenting multimodal clinical trials. Contemp Clin Trials. 2009 May;30(3):201-4. PubMed PMID: 19470310.

Borner M, Koeberle D, Von Moos R, Saletti P, Rauch D, Hess V, Trojan A, Helbling D, Pestalozzi B, Caspar C, Ruhstaller T, Roth A, Kappeler A, Dietrich D, Lanz D, Mingrone W. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Ann Oncol. 2008 Jul;19(7):1288-92. PubMed PMID: 18349029.

Gick U, Rochlitz C, Mingrone W, Pestalozzi B, Rauch D, Ballabeni P, Lanz D, Hess V, Aebi S. Efficacy and tolerability of capecitabine with weekly paclitaxel for patients with metastatic breast cancer: a phase II report of the SAKK. Oncology. 2006;71(1-2):54-60. PubMed PMID: 17344671.

Borner MM, Bernhard J, Dietrich D, Popescu R, Wernli M, Saletti P, Rauch D, Herrmann R, Koeberle D, Honegger H, Brauchli P, Lanz D, Roth AD. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol. 2005 Feb;16(2):282-8. PubMed PMID: 15668285.